Literature DB >> 1441728

A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks.

M Just1, R Berger, H Dreschsler, S Brantschen, R Glück.   

Abstract

In the near future an inactivated hepatitis A vaccine will be commercially available. The recommended vaccination schedule will include at least two vaccinations 1 month apart. Giving two doses of vaccine on the same day in one injection results in protection after 2-4 weeks dependent on the adjuvant used. Hepatitis A virus incorporated into liposomes proved to be a suitable formulation in term of rapid seroconversion, high level of mean antibody content and low reactogenicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1441728     DOI: 10.1016/0264-410x(92)90506-f

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

2.  The pH-sensitive fusogenic 3-methyl-glutarylated hyperbranched poly(glycidol)-conjugated liposome induces antigen-specific cellular and humoral immunity.

Authors:  Takehisa Hebishima; Eiji Yuba; Kenji Kono; Shin-Nosuke Takeshima; Yoshihiro Ito; Yoko Aida
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

3.  Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India.

Authors:  Hemat Jain; Vandana Kumavat; Tejinder Singh; Amanda Versteilen; Michal Sarnecki
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.

Authors:  Emily M Plummer; Marianne Manchester
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010-09-24

Review 5.  Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems.

Authors:  Ru Wen; Afoma C Umeano; Lily Francis; Nivita Sharma; Smanla Tundup; Shanta Dhar
Journal:  Vaccines (Basel)       Date:  2016-06-01

Review 6.  A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

Authors:  David B Huang; Jashin J Wu; Stephen K Tyring
Journal:  J Infect       Date:  2004-10       Impact factor: 6.072

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.